Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
Public ClinicalTrials.gov record NCT03342911. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer
Study identification
- NCT ID
- NCT03342911
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Enrollment
- 34 participants
Conditions and interventions
Conditions
- Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma
- Stage II Oropharyngeal Squamous Cell Carcinoma
- Stage III Hypopharyngeal Squamous Cell Carcinoma
- Stage III Laryngeal Squamous Cell Carcinoma
- Stage III Oral Cavity Squamous Cell Carcinoma
- Stage III Oropharyngeal Squamous Cell Carcinoma
- Stage IV Hypopharyngeal Squamous Cell Carcinoma
- Stage IV Laryngeal Squamous Cell Carcinoma
- Stage IV Oral Cavity Squamous Cell Carcinoma
- Stage IV Oropharyngeal Squamous Cell Carcinoma
- Stage IVA Hypopharyngeal Squamous Cell Carcinoma
- Stage IVA Laryngeal Squamous Cell Carcinoma
- Stage IVA Oral Cavity Squamous Cell Carcinoma
- Stage IVA Oropharyngeal Squamous Cell Carcinoma
- Stage IVB Hypopharyngeal Squamous Cell Carcinoma
- Stage IVB Laryngeal Squamous Cell Carcinoma
- Stage IVB Oral Cavity Squamous Cell Carcinoma
- Stage IVB Oropharyngeal Squamous Cell Carcinoma
- Stage IVC Hypopharyngeal Squamous Cell Carcinoma
- Stage IVC Laryngeal Squamous Cell Carcinoma
- Stage IVC Oral Cavity Squamous Cell Carcinoma
- Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions
- Carboplatin Drug
- Nivolumab Biological
- Paclitaxel Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2017
- Primary completion
- Oct 5, 2020
- Completion
- Oct 5, 2020
- Last update posted
- Apr 23, 2025
2017 – 2020
United States locations
- U.S. sites
- 3
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Abington- Jefferson Health | Abington | Pennsylvania | 19001 | — |
| Sidney Kimmel Cancer Center at Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03342911, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03342911 live on ClinicalTrials.gov.